France-based Selexis has expanded its collaboration with Agenus, a clinical-stage immuno-oncology company, by signing additional commercial license agreements, it was reported yesterday.

According to the new commercial license agreements, Agenus will leverage Selexis' modular SUREtechnology Platform for the rapid, stable, and cost-effective production of its therapeutic proteins.

The Selexis SUREtechnology Platform is claimed to improve the way mammalian cells are utilised in the discovery, development and manufacturing of recombinant proteins and drugs. It offers key significant advantages over traditional approaches, allowing speed, high-yield, stability and flexibility.